DURHAM – Aerami Therapeutics, Inc. is adding to its executive leadership team and has appointed Lisa Yañez as the biopharmaceutical company’s chief operating officer.
The company announced in December 2021 that it intended to become a publicly-traded company through a business combination with the special purpose acquisition company (SPAC) FoxWayne Enterprises Acquisition Corp.
But the two parties to that business combination mutually agreed to terminate the business combination agreement in March, according to a statement from the company published on its website, citing “unfavorable market conditions.”
Now, the company has brought on Yañez. Before, Yañez held executive positions at Acceleron Pharma and United Therapeutics, according to a statement released by the company this week.
“Lisa’s breadth and depth of experience will bring critical strategic prowess to our executive team to help grow the business and strengthen our platform opportunities,” said Steve Thornton, CEO of Aerami Therapeutics, in a statement.
The company raised $22.2 million in November 2021. In September 2019, The company changed its name from Dance Biopharm Holdings to Aerami Therapeutics after moving the to Durham from California in April of that year.
